Clay B. Thorp

Clay B. Thorp is an entrepreneur turned venture capitalist. Since 1995, he has co-founded eight companies in the life science arena and co-founded Hatteras Venture Partners in 2000. Since co-founding Hatteras, Mr. Thorp has been instrumental in building the firm from its origins with a $3 million seed fund to a venture capital partnership that manages over $450 million across five venture funds. He has led investments in a range of life science companies, including biopharmaceuticals, medical devices, diagnostics, and research informatics.

Mr. Thorp began his career in 1995 when he co-founded Xanthon, Inc., a bioinformatics company with electro-chemical detection technology for the direct analysis of DNA, RNA, and proteins. Shortly thereafter, he co-founded Novalon Pharmaceutical Corporation, where he led financing efforts and was head of business development from inception until Novalon’s sale to Karo Bio for $106.7 million in May of 2000.

Mr. Thorp has led investments and numerous strategic transaction processes in a variety of portfolio companies, including G1 Therapeutics, Clearside Biomedical, Lysosomal Therapeutics, Asthmatx, PhaseBio Pharmaceuticals, ArtusLabs, Embrella, and Synthematix.